GlobeNewsWire
25 Nov 2025, 00:00 UTC · 42w ago
Verdict
Headline takes no side. We score 6855 +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 83% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Olverembatinib demonstrated a clinical benefit rate (CBR) of 84.6% and a median progression-free survival of 25.7 months in patients with SDH-deficient GIST.
More positive than 92% of claims this week
The Phase Ib study revealed a novel mechanism where olverembatinib inhibits CD36 to block exogenous lipid uptake in tumors, a feature not seen in other available TKIs.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 76% of claims this week
The study was the largest prospective clinical trial to date for the rare SDH-deficient GIST subtype, involving 26 patients in this category.
More positive than 49% of claims this week
Which stocks this story touches
More positive than 83% of ticker scores this week
The company announced positive Phase Ib clinical trial results and a publication in a high-impact journal regarding its drug olverembatinib.
More positive than 83% of ticker scores this week
The company announced positive Phase Ib clinical trial results and a publication in a high-impact journal regarding its drug olverembatinib.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
3d ago
—
No price for 6855 right now — the quote feed didn't answer.
6855 chart →
